Objectives: We reviewed the types of monoclonal antibodies being repurposed for COVID-19 therapeutics, the clinical outcomes and adverse effects so as to provide evidence the bedside physicians, the health policy-makers and the general public could employ in the COVID-19 management protocol. Data sources: We searched PUBMED, Google Scholar and SCOPUS. In addition, snow-balling of the selected articles were carried out to identify additional potentially relevant articles. All relevant articles up to 25 May 2020 were identified. Relevant preprints were also included. Study selection: Our search strategy identified 396 potentially relevant articles which decreased to 322 after duplicates were removed. 281 articles were screened out due to lack of relevance, using the Joanna Briggs Institute’s critical appraisal checklists for evaluation of the quality of studies. The full text of the remaining 41 relevant papers were retrieved for full text evaluation after which only 19 studies from eight countries met our eligibility criteria and were included in the review. Data extraction: Three of the authors independently extracted data from the eligible journals using pre-designed MS tables. The results were compared and any conflict resolved by revisiting the journal in question. Data synthesis: A descriptive analysis of the data was performed. No formal meta-analysis was carried out due to the substantial heterogeneity between the studies. Conclusions: Monoclonal antibodies, especially tocilizumab and eculizumab hold some promise in the treatment of the disease but controlled clinical trials using them as monotherapy are needed to further evaluate this finding.